NfL (or Nf-Light) is a 68 kDa cytoskeletal intermediate filament protein expressed in neurons. NfL associates with the 125 kDa Neurofilament medium (NfM) and the 200 kDa Neurofilament heavy (NfH) to form neurofilaments. They are major components of the neuronal cytoskeleton and are believed to function primarily to provide structural support for the axon and to regulate axon diameter.
Neurofilaments get released, potentially in significant quantities, following axonal damage or neuronal degeneration. This positions NfL as a strong biomarker candidate for diverse neuropathological diseases. NfL assays that can accurately detect NfL in the blood and CSF offer valuable data for researchers investigating traumatic brain injury, multiple sclerosis, frontotemporal dementia, and other neurodegenerative diseases.
The Quanterix Simoa® NfL assay is a digital immunoassay intended for the measurement of NfL in human plasma, serum, and CSF samples and mouse serum and plasma. The antibodies also cross-react with bovine and macaque NfL epitopes, making it possible to use this assay for research in these species.
The Quanterix Simoa® NfL assay has been validated for use in clinical research and diagnostic research applications as a neurofilament light chain assay.
The Simoa® NfL assay is a valuable tool for researchers studying neuropathologies. By measuring NfL protein levels in the blood, researchers can gain insights into the role of NfL in the disease process and accelerate the path from discovery to diagnostics:
Our neurofilament light chain test supports studies in neurology, cardiology, and other fields where NfL serves as a biomarker of axonal damage.
For Research Use Only. For the Simoa® LDT NfL Test, visit our NfL LDT page.
Refer to the Simoa® NfL Advantage PLUS SR-X Compatibility Report for specifications on the SR-X platform.
The assay kit includes all necessary reagents and controls to perform 96 tests.
A: The assay is primarily used in neurology and neurodegeneration research to quantify neurofilament light (NfL), a well-established biomarker of axonal damage. Researchers use this assay to study disease progression, treatment response, and neuronal injury across a range of conditions, including Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and traumatic brain injury (TBI).
A: The assay is validated for use with human serum, plasma (EDTA), and CSF, as well as mouse serum. It allows researchers to compare data across sample types without sacrificing accuracy or sensitivity.
A: The Quanterix Simoa® NfL assay uses Quanterix’s Simoa® digital immunoassay technology, which provides higher sensitivity, a broad dynamic range, and greater reproducibility compared to standard ELISAs and other immunoassays. It supports both research and clinical development applications.
Cancer
Lung cancer is a formidable foe. Globally, it is the leading cause of cancer-related deaths in men and women, with non-small lung cancer (NSCLC) representing more than 80% of all…
The promise of proteomics lies in its ability to illuminate disease biology at scale, transform translational research, and guide the development of precision diagnostics and targeted therapies. While genomic technologies…
Translating proteomic discovery into clinical action requires more than scale, it demands precision, reproducibility, and quantitative clarity. The Quanterix Simoa® digital immunoassay technology was purpose-built to meet the demands of…
Alzheimer’s disease (AD) is increasingly understood as a multifaceted disorder involving not only amyloid and tau pathology, but also significant contributions from neuroinflammation and vascular dysfunction. In particular, astrocyte reactivity…
The 2025 Alzheimer’s Association International Conference (AAIC) brought the global neuroscience community to share breakthrough science, policy priorities, and tools like never before. It was an incredible week of conversation, innovation and…
Neurology
Next week, researchers from around the globe will gather in Toronto for the Alzheimer’s Association International Conference (AAIC) 2025, and Quanterix is proud to be at the center of the…
Neurology
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Neurology
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
Neurology
Journal of Lipid Research | August 2, 2024 Becktel DA, Frye JB, Le EH, Whitman SA, Schnellmann RG, Morrison HW, Doyle KP. J Lipid Res. 2024 https://doi.org/10.1016/j.jlr.2024.100614 Abstract Ischemic stroke…
Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends date for attaining…
Brings 20 years of senior commercial leadership in healthcare and IT, including GE Healthcare and Exact Sciences BILLERICA, Mass.–August 10, 2026–Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker…
BILLERICA, Mass. – August 6, 2026 – Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital…
BILLERICA, Mass. – August 4 2026 – Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August…
BILLERICA, Mass. – June 16, 2026 – Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15,…
BILLERICA, Mass.—June 9, 2026– Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company’s new Chief…
Strategic Leadership Addition Signals Drive to Expand Diagnostics Business BILLERICA, Mass.–June 4, 2026– Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the…
Explore our library of resources, posts and materials.
Contact our team for customer support, distributor inquiries, or general questions.
Powered by Bioz
